Ascelia Pharma AB (CHIX:ACEs)

Half Year 2026 Ascelia Pharma AB Earnings Call Transcript

Aug 20, 2026 / 08:00 AM GMT

Release Date Price: kr3.29

Transcript

Key Points

Positve

Ascelia Pharma AB (FRA:7ZA) has a strong product candidate, Orviglans, addressing an $800 million global market with orphan drug designation and compelling Phase III data.
The FDA inspections during the review process were completed without critical findings, and product quality issues have been resolved in alignment with FDA recommendations.
The company has a clear path forward with a Type A meeting scheduled for September 9th to align with the FDA on the remaining clinical imaging data questions.
Potential partners have confirmed continued interest in Orviglans despite the complete response letter, indicating the asset's commercial attractiveness.
The company has extended its cash runway into Q2 2027 through cost-saving measures, providing financial flexibility to navigate the regulatory process.
Oncoral, the second pipeline asset, shows promise as a platform for metronomic dosing of irinotecan, with potential applications across multiple tumor types.
The company has strengthened its IP position with new patent filings for packaging and manufacturing of Orviglans.

Negative

Ascelia Pharma AB (FRA:7ZA) received an unexpected complete response letter from the FDA for Orviglans, delaying approval and creating regulatory uncertainty.
The FDA raised concerns about the image read methodology, including the justification for the reread and interpretation of results, which the company disputes.
The company's cash position is limited at 38 million SEK, and the extended runway into Q2 2027 may not be sufficient if the FDA requires additional clinical trials.
The complete response letter has shifted the timeline for securing a partnership, as potential partners await clarity on the regulatory path.
The company's confidence in the data is not shared by the FDA, leading to a risk that the agency may require additional clinical evidence, increasing costs and time.
The company had to implement cost reduction actions following the complete response letter, which may impact operations and development activities.
The Type A meeting outcome is uncertain, and if the FDA does not accept the company's scientific rationale, the path to approval could be significantly delayed.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ACELP.ST - Ascelia Pharma AB
Half Year 2026 Ascelia Pharma AB Earnings Call
Aug 20, 2026 / 08:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to Acellia Pharma Q2 2026 report presentation. For the first part of the conference, participants will be in listen-only mode during the questions and answers session. Participants are able to ask questions by dialing pound key on their telephone keypad. Now I will hand the conference over to CEO Magnus Korfitsen, CFO Anton Hansen, and CSO Andreas Norlin. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, and welcome everyone to the webcast for Acelia Pharma's Q2 report for 2027.

On this call, we will be making forward-looking statements

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.